TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03889535

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resin strip crowns
Description: Technique:~I.Select shade of resin-based composite II.Rubber dam isolation III.Select primary incisor celluloid crown form with mesiodistal width similar to the tooth to be restored and trim the selected crown form to fit.~IV.Remove decay with slow speed round bur. Perform pulp therapy, if indicated. V.Reduce incisal edge by 1.5 mm VI.Reduce interproximal surfaces by 0.5 to 1.0 mm with feather edge at gingival margin. The interproximal walls should be approximately parallel.~VII.Reduce buccal surface by 1.0 mm and lingual surface by 0.5 mm with feather edge at gingival margins.~VIII. Round line angles IX.Etch for 15 to 20 seconds, rinse and air dry X. Apply bond and polymerise XI. Fill crown form to 2/3 full with composite resin and seat onto the tooth. Remove excess material with hand instrument. Polymerise.~XII. Remove celluloid crown form with scaler XIII. Finish and polish

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zirconia crowns
Description: I.Choose appropriately sized crown based on tooth's dimension; evaluate occlusion. II.Rubber dam isolation. III.Remove decay, perform pulp therapy if indicated. IV.Prep mesial half of incisal edge to complete thickness of 001 donut bur. V.Prep and blend distal half of incisal edge to create uniform incisal reduction. VI. Create chamfer margin at gum line at least half the thickness of bur tip. VII. Taper incisal half lingually to create a thin incisal edge. VIII. Remove cingulum and 0.75-1.25mm of lingual enamel; blend together forming smooth, slightly concave surface extending to tissue. IX. Thin incisal half. X.With 004 flame bur, remove chamfer margin at tissue level. Keep bur parallel to long axis of tooth. Remove chamfer in incremental steps, XI. Extend tip of bur full 2mm subgingivally. While hugging bur axially along root surface, make 3 circumferential passes. XII.Clean tooth and control bleeding. XIII.Cement crown with pure glass ionomer cement
Study: NCT01805128

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facial recognition of emotions
Description: The purpose is to consider the recognition of emotions expressed on face in patients with a schizophrenic disorder, autism and in healthy subjects.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facial recognition of emotions
Description: The purpose is to consider the recognition of emotions expressed on face in patients with a schizophrenic disorder, autism and in healthy subjects.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facial recognition of emotions
Description: The purpose is to consider the recognition of emotions expressed on face in patients with a schizophrenic disorder, autism and in healthy subjects.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: understanding metaphors
Description: Explore understanding of figurative language, including metaphor, in schizophrenic patients, autistic and healthy, and well understand how patients develop an interpretation from access to speaker's communicative intentionality (theory mind).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: understanding metaphors
Description: Explore understanding of figurative language, including metaphor, in schizophrenic patients, autistic and healthy, and well understand how patients develop an interpretation from access to speaker's communicative intentionality (theory mind).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: understanding metaphors
Description: Explore understanding of figurative language, including metaphor, in schizophrenic patients, autistic and healthy, and well understand how patients develop an interpretation from access to speaker's communicative intentionality (theory mind).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Attribution of intentionality to others in social situations depending on the type of situation
Description: Compare the style of attribution of intentions in three populations of subjects: schizophrenic, autistic and healthy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Attribution of intentionality to others in social situations depending on the type of situation
Description: Compare the style of attribution of intentions in three populations of subjects: schizophrenic, autistic and healthy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Attribution of intentionality to others in social situations depending on the type of situation
Description: Compare the style of attribution of intentions in three populations of subjects: schizophrenic, autistic and healthy.
Study: NCT02291354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pectin
Description: Patients allocated to experiment group will receive 12 g pectin each day for 12 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients allocated to experiment group will receive 12 g maltodextrin each day for 12 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Description: Standardized Frozen Fecal Microbiota will be infused via nasointestinal tube.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Fecal microbiota transplantation (FMT)
Description: Standardized Frozen Fecal Microbiota will be infused via nasointestinal tube.
Study: NCT04080440

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extubation readiness clinical score
Description: After treatment of the acute neurological condition, eligibility for a spontaneous breathing trial will be assessed once a day.~In the intervention group, after a successful spontaneous breathing trial in unconscious patients, the score will be evaluated.~If the score is \>9, extubation has to be completed

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: After treatment of the acute neurological condition, eligibility for a spontaneous breathing trial will be assessed once a day.~In the control group, after a successful spontaneous breathing trial in unconscious patients, the extubation will be achieved according to the standard of care
Study: NCT03664180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Description: IV infusion of 0.2 mg/kg/h (low-rate infusion) for at least 48h after the procedure or until discharge from CCU if it occurs later

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: 40mg/d s.c.for at least 48h after the procedure or until discharge from CCU if it occurs later

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Description: IV infusion of 10 U/kg/h (maximum 1000 U) initially, adjusted to maintain ACT between 150 and 220 seconds for at least 48h after the procedure or until discharge from CCU if it occurs later

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bivalirudin placebo
Description: Matching placebo IV infusion for at least 48h after the procedure or until discharge from CCU if it occurs later

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Enoxaparin placebo syringe
Description: Placebo syringe will be only prepared by a designated unblended medical professional on site. Placebo syringe will be presented in identical containers as a clear, colorless, sterile liquid of saline.Subcutaneous injection once a day for at least 48 hours after the procedure or until discharge from CCU if it occurs later.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Unfractionated heparin placebo
Description: Matching placebo IV infusion for at least 48h after the procedure or until discharge from CCU if it occurs later.
Study: NCT04594239

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Belotero Balance (+) Lidocaine, needle
Description: Injection of Belotero Balance (+) Lidocaine to the infraorbital hollows using needles

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Belotero Balance (+) Lidocaine, cannula
Description: Injection of Belotero Balance (+) Lidocaine into the infraorbital hollows using cannulas

Intervention type: DEVICE
Group type: OTHER
Intervention: Untreated-control / delayed-treatment, needle
Description: Untreated-control, followed by delayed-treatment with Belotero Balance (+) Lidocaine (injection of Belotero Balance (+) Lidocaine to the infraorbital hollows using needles)

Intervention type: DEVICE
Group type: OTHER
Intervention: Untreated-control / delayed-treatment, cannulas
Description: Untreated-control, followed by delayed-treatment with Belotero Balance (+) Lidocaine (injection of Belotero Balance (+) Lidocaine to the infraorbital hollows using cannulas)
Study: NCT03445013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB414 6%
Description: Twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle Comparator
Study: NCT02020577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab( erbitux®)
Description: once per week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: once per day
Study: NCT04098848

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycling exercise
Description: Intradialytic cycling exercise for 30 minutes a time
Study: NCT02058173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150 mg/daily chloroquine compare to placebo for 12 week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150 mg/daily chloroquine compare to placebo for 12 week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study: NCT01408264

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional 0.035 guidewire
Description: 0.035 guidewire

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Olympus Visiglide 0.025 guidewire
Description: 0.025 guidewire
Study: NCT02985437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surfactants

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline Solution
Study: NCT02643602

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydration with bicarbonate in addition to theophylline
Description: 0.154-molar sodium bicarbonate; 3 ml per kg bodyweight (maximum 330 ml) one hour before contrast exposure; additionally 200 mg theophylline as a short infusion; after contrast application hydration with another 1 ml per kg bodyweight per hour (maximum 110 ml per hour) for 6 hours
Study: NCT00653835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe + Simvastatin
Description: oral tablets: ezetimibe 10 mg + simvastatin 20 mg once daily for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: oral tablets: simvastatin 20 mg + ezetimibe placebo once daily for 6 weeks
Study: NCT02643602

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydration with sodium chloride in addition to theophylline
Description: 0.9% sodium chloride; 3 ml per kg bodyweight (maximum 330 ml) one hour before contrast exposure; additionally 200 mg theophylline as a short infusion; after contrast application hydration with another 1 ml per kg bodyweight per hour (maximum 110 ml per hour) for 6 hours
Study: NCT03097913

Intervention type: DEVICE
Intervention: video-stylet
Description: recording each video-stylet endotracheal tube assembly advanced through the selected nasal cavity
Study: NCT01558739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INC424
Description: Ruxolitinib was provided in 5 mg tablets, packaged in bottles. 15 - 20 mg (dose based on Baseline platelet count) twice daily.
Study: NCT02678377

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OnabotulinumtoxinA (Botox ®) Injections
Description: OnabotulinumtoxinA (Botox ®) is a neurotoxin, which inhibits acetylcholine release and temporarily relaxes the bladder muscle to inhibit urgency incontinence.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline Injections
Description: Saline will be injected into the bladder so that investigators are masked to subject randomization.
Study: NCT06192966

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Food supplement
Description: Probiotic formulation containing Lactobacillus plantarum, cranberry and vitamine C for 6 months 1 capsule/day
Study: NCT02037958

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway-Supreme
Description: Patients who receive the LMA-S

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal Tube
Description: Patients who receive endotracheal intubation
Study: NCT06192966

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo composed of maltodextrin for 6 months 1 capsule/day
Study: NCT02054728

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RHC and IMT
Description: Eligible patients subjected to RHC will be instructed on how to do RMT using the Threshold IMT® two days in advance. RMT will be conducted with 20-30% of individual inspiratory muscle strength, which will be measured beforehand. A single training session consists of 7 cycles with 2 min inspiratory training each, followed by a 1 min break (total duration 21 min).~The actual intervention consists of inspiratory muscle training (IMT) during right-heart catheterization for at least 2 min or as long as is necessary to measure all specified parameters.
Study: NCT03584217

Intervention type: DRUG
Group type: OTHER
Intervention: Iohexol Inj 300 MG/ML
Description: Diagnostic aid/agent used to measure glomerular filtration rate (GFR)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Renal Biopsy
Description: Minimally invasive outpatient procedure in interventional radiology to obtain renal tissue cores.
Study: NCT04017988

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ethanol Extracts of Porphyra Tenera(PTE10)
Description: 2 times a day, 2 capsules for 1 time, after breakfast/dinner meal, for 8 week

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 8 week
Study: NCT01903564

Intervention type: DEVICE
Intervention: magnetocardiography
Description: recording of magnetic heart activity

Intervention type: DEVICE
Intervention: magnetocardiography
Description: recording of magnetic heart activity

Intervention type: DEVICE
Intervention: postnatal ECG
Description: postnatal ECG

Intervention type: DEVICE
Intervention: fetal echocardiography
Description: fetal echocardiography

Intervention type: DEVICE
Intervention: fetal echocardiography
Description: fetal echocardiography
Study: NCT03518216

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADAPT
Description: Aim to Decrease Anxiety and Pain Treatment is a remotely delivered tailored treatment integrating mindfulness meditation and cognitive behavioral therapy. It consists of 6 sessions and blends pain and anxiety coping strategies. The first 2 sessions will be interactive with a trained psychological provider and the following 4 sessions will be web-based. Each web-based session will be followed by therapist support. The intervention is delivered through a HIPAA compliant video platform.
Study: NCT03067740

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: intraperitoneal instillation of bupivacaine 0.25% ( 2mg/kg) after excision of the appendix.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: intraperitoneal instillation of bupivacaine 0.25% ( 2mg/kg) plus dexmedetomidine 1mcg/kg after excision of the appendix.
Study: NCT03477383

Intervention type: DIAGNOSTIC_TEST
Intervention: donor-derived cell-free DNA (dd-cfDNA)
Description: Measurement of dd-cfDNA and comparison against grade of rejection as measured by endomyocardial biopsy, taken simultaneously

Intervention type: DIAGNOSTIC_TEST
Intervention: donor-derived cell-free DNA (dd-cfDNA)
Description: Measurement of dd-cfDNA and comparison against grade of rejection as measured by endomyocardial biopsy, taken simultaneously
Study: NCT01662024

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic gastric restrictive procedure
Description: Endoluminal gastric tissue approximation using an incisionless/per-oral endoscopic suturing device for primary gastric restrictive procedures
Study: NCT02497235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-935
Description: TAK-935 oral solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]MNI-792 (tracer)
Description: \[18F\]MNI-792 injection.
Study: NCT02235519

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azilsartan 40 mg.
Description: Patients will take 40 mg of azilsartan during 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azilsartan 80 mg
Description: Patients will take 80 mg of azilsartan during 12 weeks
Study: NCT04231890

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IPI monitoring
Description: Patients in this arm will have IPI monitoring
Study: NCT03613480

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Regular sessions of Motivational Interviewing at 2 weeks and then at monthly intervals for a period of 6 months
Study: NCT03400995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK0529
Description: A solution containing 300 mg radiolabelled AK0529.
Study: NCT04172896

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraperitoneal Uterosacral Ligament Suspension
Description: Vaginal intraperitoneal uterosacral ligament suspension performed by transfixing the ligament, intraperitoneally, in the intermediate portion (at the level of or above ischial spine plane) with three delayed absorbable 0 sutures, performed bilaterally (three sutures per side; six sutures total).
Study: NCT04314167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lowering cholesterol concentrations by PCSK-9 inhibitor
Description: Patients will receive the PCSK9-inhibitor Evolocumab as part of routine clinical management within the indication of this drug.
Study: NCT00895349

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT Abdomen and Pelvis scan + whole body PET-CT scan
Description: Pre-treatment scan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CT Abdomen and Pelvis scan
Description: Pre-treatment scan
Study: NCT00532948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine [Xeloda]
Description: 500mg/m2 po bid (starting dose)
Study: NCT03378011

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: phototherapy
Description: phototherapy either UVA1 or topical PUVA on acral vitiligo

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: phototherapy
Description: phototherapy either UVA1 or topical PUVA on acral vitiligo
Study: NCT01096446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Fat Emulsions
Description: Control Group: 0.5 grams/kg/day Experimental Group: 2 grams/kg/day

Intervention type: DRUG
Group type: OTHER
Intervention: Intravenous Fat Emulsions
Description: Control Group: 0.5 grams/kg/day Experimental Group: 2 grams/kg/day
Study: NCT02195791

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone 30mg/tab (oral) 1 tab once daily for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (oral) 1 tab once daily for 7 days
Study: NCT00915005

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Photon Therapy
Description: Group 1: 74 Gy 37 radiation treatments, given 5 days a week for about 7 1/2 weeks. Each daily treatment should take about 20-30 minutes to complete.
Study: NCT01182246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXP107-11
Description: The drug substance, AXP107-11, is a crystalline form of genistein, a substance shown in literature data to target pancreatic tumor cells and also the tumor microenvironment and thus sensitizes tumors to chemotherapy. AXP107-11 is formulated in a capsule containing 2x100 mg of active substance.~A maximum of four cohorts of three to six patients each will be treated with escalating dose levels of AXP107-11 alone (two weeks) and in combination with gemcitabine (one week).~AXP107-11 capsules will be ingested orally twice daily (morning and evening) each day of the treatment period. In phase Ib, AXP107-11 will be administered once daily on the first treatment day (morning), followed by twice daily administrations continuously throughout the treatment period. When a minimum of six patients have been treated and evaluated on the maintenance dose (phase 1b), additional patients will be included directly into phase IIa.
Study: NCT04526925

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respiratory filter in-line placed with the standard mouthpiece
Description: The respiratory filter is a device that removes solid/large particles from gas

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard mouthpiece
Description: The mouthpiece is the interface that is placed on participant's face in order to measure all the breathing physilogic responses
Study: NCT04172896

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extraperitoneal Uterosacral Ligament Suspension
Description: Vaginal extraperitoneal uterosacral ligament suspension performed by transfixing the ligament, extraperitoneally, in the intermediate portion (at the level of or above ischial spine plane) using a suture capturing device with two delayed absorbable 0 sutures, performed bilaterally (two sutures per side; four sutures total).
Study: NCT00970073

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thymoglobulin 3mg total
Description: 1.5 mg/kg induction on Day 0 and 1.5 mg/kg induction on Day 2 (total of 3 mg/kg)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thymoglobulin 4.5mg total
Description: 1.5 mg/kg induction on Days 0, 2 and 4 (total 4.5 mg/kg)
Study: NCT03908528

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid Plus Chemotherapy (doxorubicin (also known as Adriamycin) plus cyclophosphamide followed by taxol)
Description: 600 mg Alpha-lipoic acid daily (an antioxidant that's in many foods, and it's made naturally in the investigator's bodies) with four cycles of doxorubicin (also known as Adriamycin) plus cyclophosphamide followed by weekly taxol for 12 weeks..

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Plus Chemotherapy (doxorubicin (also known as Adriamycin) plus cyclophosphamide followed by taxol)
Description: Placebo with four cycles of doxorubicin (also known as Adriamycin) plus cyclophosphamide followed by weekly taxol for 12 weeks.
Study: NCT01782755

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L. rhamnosus GG - Probiotic
Description: Twice daily, patients will receive either 1x1010 colony forming units (CFU) of L. rhamnosus GG (Culturelle, Locin Industries Ltd) in 1 capsule or an identical placebo capsule

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Microcrystalline Cellulose
Description: Placebo capsule, twice daily (containing Microcrystalline Cellulose)